Corporate Announcement Under Regulation 30 of SEBI (LODR) Regulations, 2015 about the completion of US FDA Remote Interactive Evaluation (RIE) of JSTL.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The US FDA conducted a Remote Interactive Evaluation (RIE) of Jeevan Scientific Technology's Clinical Pharmacology facility from October 17 to November 6, 2025. The review covered the company's BA/BE (bioavailability/bioequivalence) studies along with its operations, systems, and procedures. The evaluation was completed successfully with no critical observations noted by the regulator. This indicates the company's clinical research facility meets US FDA's quality and compliance standards. Jeevan Scientific provides clinical and bioanalytical services, and BA/BE studies are a key revenue area supporting generic drug approvals globally.
Positive for shareholders — passing a US FDA inspection with no critical observations reinforces the company's regulatory credibility and supports continued business in clinical pharmacology and bioequivalence studies, which are critical to its service offerings.